secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2026-06-26T20:48:50+00:00
Accession:  0001628280-26-045804
Event type: other
Sentiment:  neutral
Materiality: 0.00
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Therapeutics stockholders elect three Class II directors at 2026 annual meeting
--------------------------------------------------------------------------------

- Three Class II directors elected: Evert Schimmelpennink, Lori M. Lyons-Williams, and Diego Miralles, M.D.
- Broker non-votes of 6,133,812 shares on each director election.
- Ratification of Ernst & Young LLP as independent auditor for FY 2026: 28,021,047 votes for, 16,104 against.
- Record date April 27, 2026; 32,723,877 shares of Class A common stock outstanding and entitled to vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000162828026045804/0001628280-26-045804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000162828026045804/ctnm-20260626.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-045804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer